Minimising the risks of allergen-specific injection immunotherapy.
about
The anti-vaccination movement and resistance to allergen-immunotherapy: a guide for clinical allergistsGuideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical AssoImmediate-type allergy to drugs and related compounds: evaluation and management.Undertreatment of allergy: exploring the utility of sublingual immunotherapy.A review of clinical efficacy, safety, new developments and adherence to allergen-specific immunotherapy in patients with allergic rhinitis caused by allergy to ragweed pollen (Ambrosia artemisiifolia).Clinical practice: Allergen-specific immunotherapy in children: facts and FAQs.A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy.Looking ahead at the potential benefits of biotechnology-derived allergen therapeuticsEAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis.Off-label use of omalizumab in non-asthma conditions: new opportunities.
P2860
Q24595355-D07DAD5F-FB24-4900-B557-B2B8C94A4FECQ35777126-9C80219C-D9F5-4617-94E5-949BC5810260Q36406780-8C079F9C-4415-4239-B239-193CA1EC2DCFQ37459337-84ED627E-5FD0-40B1-AE94-520D79FD5EB8Q37652965-88452C93-A73F-4D1A-B7CB-CC1412748D54Q37820336-F705B91C-74FC-42D3-B54F-C73F218205CAQ39259292-4F815ED6-863E-42A3-848B-7957B8F77A77Q42467716-34E33A3B-08F9-4217-A06C-A87FD70C4774Q47764778-E6A0C3F2-C8A1-4D0E-98EB-16A0C76291D3Q51770958-D804DE8D-3A89-4D47-B3F6-7305BF8F8652
P2860
Minimising the risks of allergen-specific injection immunotherapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Minimising the risks of allergen-specific injection immunotherapy.
@ast
Minimising the risks of allergen-specific injection immunotherapy.
@en
Minimising the risks of allergen-specific injection immunotherapy.
@nl
type
label
Minimising the risks of allergen-specific injection immunotherapy.
@ast
Minimising the risks of allergen-specific injection immunotherapy.
@en
Minimising the risks of allergen-specific injection immunotherapy.
@nl
prefLabel
Minimising the risks of allergen-specific injection immunotherapy.
@ast
Minimising the risks of allergen-specific injection immunotherapy.
@en
Minimising the risks of allergen-specific injection immunotherapy.
@nl
P1433
P1476
Minimising the risks of allergen-specific injection immunotherapy.
@en
P2093
H J Malling
P304
P356
10.2165/00002018-200023040-00005
P577
2000-10-01T00:00:00Z
P6179
1001944718